MDGL
Madrigal Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +20.0% ·
share flow -2.1% ·
net new positions +16.7%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 121 | +1 | 10.47M | $5.62B | +9 | −9 |
| Q1 2026 | 124 | +7 | 12.07M | $6.32B | +9 | −3 |
| Q4 2025 | 116 | 0 | 12.47M | $7.26B | +1 | n/a |
| Q3 2025 | 19 | +1 | 6.80M | $3.12B | +1 | −1 |
| Q2 2025 | 16 | 0 | 6.45M | $1.95B | n/a | n/a |
| Q1 2025 | 13 | +1 | 2.28M | $753.61M | +1 | n/a |
| Q4 2024 | 12 | +2 | 2.15M | $662.73M | +2 | n/a |
| Q3 2024 | 9 | +1 | 1.41M | $299.66M | +3 | −2 |
| Q2 2024 | 8 | n/a | 1.43M | $401.79M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 781.29K | n/a | $241.08M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 588.76K | -19.8% | $181.68M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 410.58K | +1.2% | $126.72M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | Renaissance Technologies ✦ | 160.78K | +261.3% | $49.61M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 5 | Norges Bank ✦ (passive) | 115.09K | +64.5% | $35.51M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 23.84K | New | $7.36M | 0.0% | New | 1 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 19.96K | New | $6.16M | 0.0% | New | 1 | SEC ↗ |
| 8 | Marshall Wace ✦ | 17.49K | -78.2% | $5.40M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 9 | Citadel Advisors ✦ | 14.87K | -72.8% | $4.59M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 10 | Wellington Management ✦ | 8.17K | -9.5% | $2.52M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 11 | AQR Capital Management ✦ | 5.48K | +7.1% | $1.69M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 12 | Millennium Management ✦ | 1.31K | -85.3% | $405,461 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $7.36M | 0.0% |
| Adage Capital Partners | $6.16M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 374 holders, 23.71M shares, $12.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 120 sh · $65,565
Officer, Director · 60 sh · $31,985
Officer, Director · 106 sh · $56,611
Officer, Director · 218 sh · $116,836
Officer, Director · 160 sh · $86,019
Officer, Director · 687 sh · $371,382
Officer, Director · 368 sh · $199,324
Officer, Director · 1.20K sh · $652,209
Officer, Director · 1.54K sh · $837,253
Officer, Director · 761 sh · $414,616
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology